The Asia Pacific trial sector grew during the global economic downturn as sponsors sought to improve access to patients, cut costs and improve data quality according to Novotech CEO Alek Safarian.
Questions about the ethics and scientific validity of trials conducted under the Pediatric Exclusivity Provision have been raised after researchers found many studies used sites outside the US.
Cyprotex launches in vitro toxicology service, Cyprotox, after extending laboratory space at its Macclesfield, UK facility by 90 sq m. This gives the UK site the same in vitro capabilities as those of Apredica, US, which Cyprotex acquired in August.
Proposed changes to USP chapters 232 and 233 on trace impurities would increase drug industry use of automated analysis, creating “huge number” of potential new customers says Thermo Fisher Scientific.
The FDA has approved Alexion Pharmaceuticals’ Rhode Island, US plant for commercial supply of Soliris (eculizumab), giving the biopharm a second source.
The US Alzheimer’s Association has created ‘TrialMatch’, a free online tool enabling people with Alzheimer’s or related dementias to actively search for opportunities to enrol in clinical research trials.
Spaulding Clinical has renovated its Phase I pharmacology unit, citing both sponsor and regulatory demand for centralized cardiac monitoring as drivers.
Chemir Analytical Services launches custom synthesis service for organic molecules for drug R&D, aimed at small pharma companies with rush or emergency projects.
Parexel has collaborated with Stora Enso to add an integrated temperature recording system which can save up to 48 hours compared to traditional cold chain.
The US HHS is allocating $2bn (€1.6bn) to overhaul pandemic and bioterrorism capabilities through improvements to regulatory, developmental and manufacturing processes.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including J&J strengthening manufacturing and appointments at Alexza and Inspire.
SAFC and Novozymes Biopharma have agreed to extend their partnership by ten years for the exclusive distribution of LONG R3 growth factor, used for industrial cell culture applications.
Improving safety and efficacy coupled with drug industry desire for “stronger” patents will drive growth of the biologics sector over the next five years, according to new research.
Producing conjugate vaccines in recombinant E coli is potentially simpler and more cost-effective than alternatives, say researchers, but the method suffers from low yields.
Drug industry focus on clinical data quality, cost and speed is key driver for recent growth of Hungarian trials business says patient recruitment specialist Synexus.
A Japanese pharmaceutical company has contracted UK-based Quay Pharma to make trial stocks of two NCEs used to treat genitourinary disorders. One of the products will be entering the first phase of its clinical studies in Europe, while the second is progressing...
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at Quintiles, WuXi, NeoGenomics and BASi.
Bioanalytical Systems, Inc (BASi) posted an operating profit in the third quarter, overturning a loss 12 months ago, as lower expenses offset a slight dip in revenue.
Warnex says demand for contract analysis services increase in Q2 thanks to expansion in diagnostics market and forecasts growth opportunities in India.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including Ranbaxy’s CEO stepping down and appointments at Avid, the USP and Novavax.
Furiex posts Q2 loss as increased R&D spending and higher admin costs offset revenue gains, but firm is confident development model can boost partners’ pipelines.
Datatrak has posted an operating profit, grown revenues and recorded the forth consecutive quarter-on-quarter increase in backlog in its latest results.
US drugmaker Merck & Co has announced plans to reacquire a Pennsylvania manufacturing plant to guarantee supply of key active pharmaceutical ingredient (API).
Lower overseas demand from key customers hurt fine chemicals maker Synthetech in first quarter fiscal 2011, continuing the decline seen in the previous financial year
